We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Evaclite manufactures dynamic exit signs designed to make buildings safer and save lives. The company argues that its products are 77% more visible than conventional exit signs and reduces congestion at exits by 36%. The company received the 2018 FIREX - Fire Innovation of the Year Award. It also won the Safety and Health Excellence (SHE) Award in 2019 and 2020. Evaclite counts companies like Apple, CBRE, BBC, Melia, and MetroBank amongst its clients. The company has inquiries from over a dozen countries globally with a 12-month sales opportunity pipeline of over £1.5 million. It will use 60% of the investment to build its sales team, 28% to boost its inbound marketing campaign, 7% to develop additional intellectual property, and 5% towards overhead and general costs.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £148,736
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Podcast Radio (PR) is the Ofcom-licensed UK digital broadcast radio station showcasing podcasts 24/7 globally. It is currently broadcasting in Surrey, Manchester, London, and Glasgow. Podcasting is expected to become a $3.3 billion industry by 2025. PR aims to be a disruptor in this segment. PR got front-page coverage in the international edition of Radio World magazine and has onboarded US radio Disc Jockey (DJ) Gene Baxter. The company will use 15% of the investment to secure digital radio broadcast transmission in 5 more UK cities by the end of 2020, 15% to partner with applicants for new digital radio transmitters, 15% to create a PR-led UK marketing campaign supported by social media, 25% to recruit new staff members, 10% to develop its on-air content, 10% to develop its website and application, and 10% to build new business partnerships to drive the international expansion of the company.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £149,023
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Propetly is an online platform that acts as a connecting hub between investment providers and global investors in the field of real estate. It enables potential property investors to find, evaluate and calculate their investment project within minutes. With the help of AI-enabled architecture, Propetly can verify transactions on its portal, suggest finance options and ensure complete diligence of the transaction as per industry benchmarks. Given the relative lack of professional and up-to-date property investors in the UK, Propetly aims to become the one-stop-shop for all real estate deals. Its offering has led to Propetly being counted amongst leading PropTech brands in the UK. With the funds received, Propetly will invest in paid advertising and PR, upgrade its AI systems to enable more options are available to customers across wide demographics and human resources.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £235,079
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £134,892
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £445,814
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
The Landsite is the UK's first online property portal that connects various entities within the property industry such as developers, legal services, insurance advisors and architects, to one another, simplifying the process of finding and buying a property. By registering with The Landsite, a business/professional can list their business as operating in a specific region of the country and appear against all property searches that take place in that same region. The user then needs to put in their postcode or address and can then access properties within that region, as well as, seek available professional guidance to zero in upon a potential purchase. The platform also has an insights page that aims to become a recruitment, training and educational hub for the property industry. The company will use the investment to grow its business across different verticals.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Antaco is a company that deals in waste management by converting it into neutral solid biofuel using their patented technology. The global water sector is estimated to present a £15 billion opportunity. To date, the company has raised £5.8 million, including an £857,000 grant from the UK government and has also signed a contract with its first customer (Swiss Public Utility). With the proceeds, the company will build up their in-house capacity, increase enhancement of existing plant and hire subcontractors to install and commission plant.

Pitch Rated

77%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £570,840
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph